A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)

Authors:

Abstract
No abstract available
Funding Information
  • National Cancer Institute (P30CA008748)
  • National Institutes of Health

This publication has 23 references indexed in Scilit: